Recruiting Clinical Trials

Displaying 61 - 70 of 245 result(s)
Study Title Condition Phase Location
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis) Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants Cryptosporidium Infection, Cryptosporidiosis Phase 1
  • Country: 
    United States
A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration Neovascular Age-related Macular Degeneration Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
An Open-label, Single-arm, Multicenter Study in Patients With Neovascular Age-related Macular Degeneration to Evaluate the Safety of SOK583A1 (40 mg/mL), a Proposed Aflibercept Biosimilar Product, Provided in a Vial Kit Neovascular Age-related Macular Degeneration (nAMD) Phase 3
  • Country: 
    United States
A Phase IV, Multi-center, Open-label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of EGATEN™ (Triclabendazole) in Patients (6 Years of Age or Older) With Fascioliasis. Fascioliasis Phase 4
  • Country: 
    Colombia
  • Country: 
    Vietnam
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticostero ... Lupus Nephritis Phase 2
  • Country: 
    United States
  • Country: 
    Germany
  • Country: 
    Hungary
  • Country: 
A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-r ... Neoplasms Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Netherlands
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent Glioblastoma Phase 1
  • Country: 
    France
  • Country: 
    Portugal
  • Country: 
    Spain
  • Country: 
A Real-world, Prospective, Multicenter Study to Assess the Safety and Effectiveness of Secukinumab (Cosentyx®) in Patients Aged 6 to Less Than 18 Years With Moderate to Severe Chronic Plaque Psoriasis in China Moderate to Severe Chronic Plaque Psoriasis Not Given
  • Country: 
    China
Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS Multiple Sclerosis Phase 3
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
    Italy
  • Country: